Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer

ConclusionIn this heavily pretreated population including everolimus, fulvestrant plus palbociclib provides an mPFS of 5.8  months with the same magnitude of benefit for fulvestrant-pretreated patients.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research